Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 01, 2024
Syncromune Receives FDA IND Clearance for SYNC-T SV-102 in Prostate Cancer
Details : SYNC-T SV-102 therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug, a personalized therapeutic approach for metastatic castrate-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 30, 2024
Syncromune Granted FDA Fast-Track for SYNC-T SV-102 for Metastatic Prostate Cancer
Details : SV-102 is an investigational vaccine utilising compamy's innovative SYNC-T platform, given as intratumoral infusion, for the treatment of metastatic castrate-resistant prostate cancer.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : YH002
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucure’s YH002, and multiple other active ingredients as part of the Syncrovax...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : YH002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Eucure Biopharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 16, 2022
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 16, 2022